ArticleJournal of the National Cancer Institute2025
Incidence of rare cancers during the COVID-19 pandemic: a US population-based study.
Article in Journal of the National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of the COVID-19 pandemic on cancer incidence, stage, mortality, and short-term survival in Ireland: a population-based analysis.ESMO real world data and digital oncology · 2026Article
- Spontaneous rupture of a giant thymoma causing hemothorax and cardiopulmonary collapse.Respiratory medicine case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionRecent media reporting has suggested an increase in the incidence of rare cancers in 2021 as a result of the COVID-19 pandemic, raising concern for possible carcinogenic effects of severe acute respiratory syndrome coronavirus 2 infection. We aimed to identify cancers that increased in incidence in the United States during 2021 compared with 2018-2019.
methodsWe analyzed data from Surveillance, Epidemiology, and End Results (SEER-22) using a systematic classification schema including rare cancers. We estimated age-standardized incidence rate ratios (aIRRs) comparing the year 2021 to 2018-2019 for 693 individual cancer types and highlight those with an aIRR > 1 based on a Bonferroni-corrected P-value threshold. Cancer types of particular interest included cholangiocarcinoma, diffuse large B-cell lymphoma, Kaposi sarcoma, and lung cancer.
resultsAmong 693 unique cancer types evaluated, 9 showed a significant increase in incidence in 2021 compared with 2018-2019 and did not also increase in prior years, including 4 subtypes of thymoma (type-A aIRR = 2.50; type-AB aIRR = 2.78; type-B aIRR = 1.90; type not otherwise specified aIRR = 1.60), granulosa cell tumor of the ovary (aIRR = 2.72), peripheral neuroectodermal tumors of the bone (aIRR = 10.6) and soft tissue (aIRR = 3.20), pheochromocytoma (aIRR = 4.59), and paraganglioma (aIRR = 3.30). Increases for all 9 cancer types could be attributed to changes in cancer registry reporting practice. Cancer types of particular interest did not increase in incidence during 2021. DISCUSSION AND
conclusionOur study does not support an increase in cancer incidence in the United States in 2021 due to the COVID-19 pandemic. It is important to monitor future trends, which may reveal longer-term effects of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.